Pneumococcal Vaccines Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

Industry Outlook

The global pneumococcal vaccines market held US$ 7,108.7 Mn in 2020 and expected to grow at compound annual growth rate (CAGR) of 5.1% during the forecast period from 2021 to 2029. Pneumococcal diseases are one of the leading cause of serious illness globally resulting in high number of hospitalization every year. Diseases caused by pneumococcus bacteria include pneumonia, otitis media, sinus, meningitis and sepsis. According to National Foundation of Infectious Diseases (NFID), more than one million adults in the U.S. suffer from pneumococcal pneumonia every year and close to half a million people hospitalizations occur annually in the United States. The burden of pneumococcal diseases is higher in children below 5 years old and adults above 65 years. Developing countries are the most affected by pneumococcal diseases, for instance, India holds the highest number of global pneumonia deaths, accounting for 20 percent of worldwide pneumonia deaths in children below the age of 5. However, constant initiatives by government across the world and private health organizations there has been significant reduction in number deaths occurring, especially in developing countries.

The market players operating in the market are focusing on low income countries and developing countries by investing and partnering with local players to maintain the supply of vaccines in the region. North America held the largest share in the global pneumococcal vaccines market owing to the domicile of two major pneumococcal vaccines producers (Pfizer, Inc. and Merck & Co., Inc.) in the region. Pneumococcal conjugate vaccines produced by these pharma giants is part of the routine vaccine program in the U.S. and Canada. Asia Pacific and Latin America are projected to witness significant growth during the forecast period owing to high burden of pneumococcal diseases in the region and supportive government policies rendering market growth.

13-valent PCV Set to Drive the Market of Pneumococcal Vaccines Market

In 2020, 13-valent PCV vaccine held the largest share in the global pneumococcal vaccines market. PVC13 offers a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The Centers for Disease Control and Prevention (CDC) PCV13 vaccines for children below 2 and adults above 65 years of age. Moreover, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against various serotypes of pneumococcus. Moreover, Pfizer’s 20-valent PCV and Merck’s 15-valent PCV are in the late stage of the clinical trials and expected to enter the market during the forecast period, which will further provide thrust to pneumococcal market.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2021 to 2029.

Report Scope by Segments

Pneumococcal Vaccines market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on vaccine type, product type, and geography.

By Vaccine Type (2019-2029; US$ Mn)

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

By Product Type (2019 - 2029; Mn)

• 10-valent PCV
• 13-valent PCV
• 23-valent PPSV
• Pipeline Analysis
• 15-valent PCV
• 20-valent PCV

Geography Segment (2019-2029; US$ Mn)

• North America (U.S. and Canada)
• Europe (U.K., Germany, and Rest of Europe)
• Asia Pacific (Japan, China, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)

Market is studied in order to understand the current dynamics and future trends in the global pneumococcal vaccines market. The study includes market size and forecast for all considered segments presented in the report for the period from 2019 to 2029, along with respective compound annual growth rate (CAGRs) for the forecast period from 2021 to 2029, considering 2020 as the base year. The key players currently engaged in pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc. and GlaxoSmithKline plc.

Key questions answered in this report

• How the global pneumococcal vaccines market will perform during the forecast period from 2021 to 2029?
• What are the latest trends in the pneumococcal vaccines market and valuable opportunities for key players?
• Who are the leading players in the global pneumococcal vaccines market?
• Which is the leading/and fastest region in the global pneumococcal vaccines market?
• What are drivers and restrains governing the global pneumococcal vaccines market?
• What is the epidemiology of pneumococcal diseases worldwide?
• How is the pipeline of the pneumococcal vaccines?

This product will be delivered within 2 business days.